{
  "name" : "twin.sci-hub.se_6313_18b6c0ba9cb0bafdb8fc064a14550977_nano2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian Randomization study",
    "authors" : [ "Jana Nano", "Taulant Muka", "Symen Ligthart", "Albert Hofman", "Sarwa Darwish Murad", "Harry LA Janssen", "Oscar H Franco", "Abbas Dehghan" ],
    "emails" : [ "a.dehghan@erasmusmc.nl" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Background: High levels of serum gamma-glutamyltransferase (GGT) are associated with increased risk of prediabetes and type 2 diabetes in observational studies. It is unclear whether this relationship is causal, arises from residual confounding or is a consequence of reverse causation. Methods: We used data from a prospective population-based cohort study, compromising 8611 individuals without diabetes at baseline. Cox proportional hazard models were used to study the association between serum GGT levels and incident prediabetes and diabetes. A Mendelian Randomization (MR) study was performed using a genetic risk score consisting of 26 GGT-related variants, based on a genome-wide association study (GWAS) on liver enzymes. Association with diabetes and glycaemic traits were investigated within the Rotterdam Study and large-scale GWAS. Results: During follow-up, 1125 cases of prediabetes (mean follow-up 5.7 years) and 811 cases of type 2 diabetes (6.9 years) were ascertained. The predicted hazard ratios per standard deviation (SD) change in GGT levels in the multivariable model were 1.10 for prediabetes [95% confidence interval (CI): 1.02–1.19] and 1.19 for type 2 diabetes (95% CI: 1.10–1.30). The genetic risk score associated with increased GGT levels (beta per SD log GGT¼ 0.41, 95% CI: 0.35–0.47), explaining 3.5% of the observed variation in GGT. MR analysis did not provide evidence for a causal role of GGT, with a causal relative risk for prediabetes and type 2 diabetes per SD of log GGT of 0.97 (95% CI: 0.91–1.04) and 0.96 (95% CI: 0.89–1.04), respectively. Multiple instrumental analysis using genetic associations with type 2 diabetes and glycaemic traits from previous GWA studies detected no causal effect of GGT.\nVC The Author 2017; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 1\nConclusions: MR analyses did not support a causal role of GGT on the risk of prediabetes or diabetes. The association of GGT with diabetes in observational studies is likely to be driven by reverse causation or confounding bias. As such, therapeutics targeted at lowering GGT levels are unlikely to be effective in preventing diabetes.\nKey words: Type 2 Diabetes; prediabetes; gamma-glutaryltransferase; Mendelian Randomization"
    }, {
      "heading" : "Introduction",
      "text" : "Circulating serum levels of gamma-glutamyltransferase (GGT) have been associated with increased risk of prediabetes and type 2 diabetes in observational studies.1 A meta-analysis of 24 cohorts reported 34% higher diabetes risk in a comparison of extreme thirds of baseline levels of GGT.1 It is, however, unclear whether the association between GGT and diabetes is free of unobserved confounding. In addition, serum levels of liver enzymes could be changed as a consequence of type 2 diabetes pathology (i.e. reverse causality). Therefore, a causal role of GGT on type 2 diabetes is uncertain.\nIn recent years, genetic information has been used to infer causality in the pathogenesis of complex diseases. The inference is based on the fact that alleles are allocated randomly during gamete formation; therefore, genetic variants are inherited independently of potential confounding. A previous study from Switzerland (4360 individuals) used a single-nucleotide polymorphism (SNP) in the GGT1 gene to study the causal relation between GGT and fasting insulin levels employing a Mendelian Randomization (MR) approach.2 This SNP explains merely 1.2% of the variation in GGT levels in this study. It is known that a weak instrumental variable makes the association susceptible to false positive findings.3 So far, 26 loci have been identified for serum GGT levels.4 Thus, a genetic risk score (GRS) combining the effect of all these loci could provide a stronger instrument for the MR analysis to infer causality.5 Additionally, GGT has not been previously investigated as a causal biomarker for diabetes, as reported from a recent systematic review from Abbasi.6\nIn this study, we investigated the association between serum GGT levels and risk of incidence prediabetes and\ntype 2 diabetes in a large prospective population-based cohort study of participants aged 45 years. Using a MR approach, we created a GRS incorporating 26 variants that are identified for serum GGT levels in a genome-wide association study (GWAS) and examined its association with prediabetes and type 2 diabetes. Next, we investigated the causal effect of GGT on diabetes and glycaemic traits by using summary-level data from previous GWAS consortia."
    }, {
      "heading" : "Methods",
      "text" : "Study population\nThe study was performed among participants of the prospective population-based Rotterdam Study. In 1989, all residents aged 55 years or older in Ommoord, a suburb of Rotterdam, The Netherlands, were invited to participate in the study (RS-I). Seventy-eight per cent of the invitees agreed to participate (n¼ 7983). In 1999, the Rotterdam Study was extended by including 3011 participants from those who either moved to Ommoord or turned 55 (RS-II). The third cohort was formed in 2006 and included 3932 participants aged 45 years and older (RS-III). There were no eligibility criteria to enter the Rotterdam Study cohorts except the minimum age and residential area based on postal codes. Participants have been re-examined every 3–4 years, and have been followed up for a variety of diseases. A more detailed description of the Rotterdam Study can be found elsewhere.7 The Rotterdam Study has been approved by the medical ethics committee according to the Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. All participants in the present analysis\nKey Messages\n• Observational evidence shows a strong association between a-glutamyltransferase(GGT) levels and prediabetes and\ntype 2 diabetes risk, but the results of a large Mendelian Randomization Study do not support a causal relationship.\n• The lack of association between genetically raised GGT levels and diabetes suggests that increased levels of GGT\nmight be a response to the disease process rather than a cause of the disease.\n• These findings suggest that interventions designed to lower GGT levels are unlikely to decreases the risk of develop-\ning diabetes.\nprovided written informed consent to participate and to obtain information from their treating physicians. We used the third visit of the first cohort (1997–99) and the first centre visit for both the second cohort (2000–01) and the third cohort (2006–08) as baseline. We excluded 314 participants with no informed consent, 1376 participants with no fasting glucose measurement and 219 other participants with no information on GGT. Next, we excluded individuals with prevalent type 2 diabetes or prediabetes depending on the studied outcome (Figure 1). To perform the genetic investigation, participants were further excluded due to lack of genotyping data, leaving the total number of participants per analysis 6236 for prediabetes and 7383 for diabetes.\nMeasurement of gamma-glutamyltransferase\nFasting blood samples were collected by venipuncture, and immediately frozen at 20 C. Serum GGT was determined within 2 weeks using a Merck Diagnostica kit on an Elan Autoanalyzer Merck. All liver biochemistry measurements\nwere obtained in the laboratory of the Department of Epidemiology, Erasmus University Medical Center.\nAscertainment of prediabetes and type 2 diabetes\nThe participants were followed from the date of baseline centre visit onwards. At baseline and during follow-up, cases of prediabetes and type 2 diabetes were ascertained through active follow-up using general practitioners’ records, glucose hospital discharge letters and glucose measurements from the Rotterdam Study visits. According to the WHO guidelines, prediabetes was defined as a fasting blood glucose between 6.0 mmol/L and 7.0 mmol/L and type 2 diabetes was defined as a fasting blood glucose >7.0 mmol/L, or the use of blood-glucose-lowering medication.8 Information regarding the use of blood-glucoselowering medication was derived from both structured home interviews and linkage to pharmacy records. At baseline, more than 95% of the Rotterdam Study population was covered by the pharmacies in the study area. All potential events of prediabetes and type 2 diabetes were\nindependently adjudicated by two study physicians. In case of disagreement, consensus was sought with a specialist. Follow-up data were complete until 1 January 2012.9 Information on study model covariates can be found in Supplementary Table 1 (available as Supplementary Data at IJE online).\nGenotyping\nGenotyping was conducted in self-reported White participants in all three cohorts using the Illumina Infinium HumanHap550K Beadchip in RS-I and RS-II and the Illumina Infinitum HumanHap 610 Quad chip in RS-III at the Genetic Laboratory of the Erasmus MC, Department of Internal Medicine, Rotterdam, The Netherlands. Participants were excluded if they had excess autosomal heterozygosity, mismatch between called and phenotyping sex, or recognized as being outlier with identical-by-state clustering analysis. Before imputation, SNPs with minor allele frequency (MAF)<0.01, call rate<95% and departure from Hardy-Weinberg equilibrium cut-off P-value 1 10–6 were excluded. SNPs were imputed based on the 1000 Genomes cosmopolitan phase 1 version 3 reference.\nConstruction of the GRS\nWe searched PubMed using key words ‘genome-wide association study’, ‘GWAS’, ‘gamma-glutamyltransferase’ and ‘GGT’ and identified one of the largest genome-wide association studies conducted on 61 089 individuals of European descent. In this study, we selected 26 SNPs that passed the genome-wide significance threshold (P-value< 5 10–8) for serum GGT levels.4 Supplementary Table 2 (available as Supplementary Data at IJE online) provides an overview of the SNPs included in the genetic score for GGT and weights assigned to each SNP. The effect allele (coded 0–2) was the GGT raising allele. We then calculated the GRS by multiplying the number of risk alleles at each locus by corresponding reported betacoefficient and summed the products.\nStatistical analysis\nFor the observational association between GGT and prediabetes and type 2 diabetes, we estimated hazard ratios (HRs) in four adjusted Cox proportional hazard models. Model 1 was adjusted for age, sex and study cohort. Model 2 was further adjusted for body mass index (BMI) and alanine aminotransferase (ALT). In model 3, potential risk factors and confounders of type 2 diabetes were added to model 2 including total and high-density lipoprotein (HDL) cholesterol, triglycerides, CRP (C-reactive protein),\nwaist circumference, current smoking status, systolic blood pressure, anti-hypertensive medication use, lipid-lowering medication use, prevalent cardiovascular disease (CVD), fasting insulin and fasting glucose levels. CRP, ALT, insulin and HOMA-IR were natural log-transformed. As GGT was not normally distributed, we log-transformed prior to analysis, enabling us to express associations as ‘per standard deviation (SD) of log-transformed GGT levels’ in both observational and MR analyses.\nAssociations of individual SNPs and GGT genetic score with GGT levels were assessed with linear regression analysis among participants in the Rotterdam Study. SNPs were modelled per GGT-increasing allele (additive model) and, together with MR results, estimates reflect per-SD change in GGT levels. HRs were computed using Cox proportional hazard models adjusted for study cohort. We further investigated the association of genetic score of GGT with glycaemic traits (fasting glucose, fasting insulin, HOMA-IR). The genetic analysis was repeated in strata of alcohol intake (drinkers vs non-drinkers) and we investigated whether there was a trend between alcohol categories and the GRS. In a sensitivity analysis, participants with prevalent CVD were excluded. To increase the sample size, we examined the association of GRS with a combination of both prevalent and incident type 2 diabetes cases. Taking into consideration any pleiotropic effect of the SNPs included in the genetic score, we reanalysed the genetic estimates excluding SNPs that have previously been reported to be associated with cardiometabolic traits (rs1260326, rs10513686, rs4074793, rs17145750, rs7310409, rs516246).4\nMR using data from MAGIC and DIAGRAM consortia\nTo maximize the statistical power, we examined the association of GGT-related genetic variants with diabetes and glycaemic traits using data from the largest GWAS metaanalyses. For diabetes, we used data from the DIAGRAM consortium, which meta-analysed genetic variants in 34 840 case subjects with diabetes and 114 981 control subjects from 37 studies.10 For fasting glucose (n¼ 58 074), fasting insulin (n¼133 000) and HOMAinsulin resistance (n¼37 073), we used data from the Meta-Analyses of Glucose and Insulin-related Traits Consortium (MAGIC), which is a collaborative effort that combined data from 55 studies to identify genetic determinants that affect glycaemic traits. Participants were of European ancestry and genotyped with the Metabochip.11 We selected 26 GGT-related SNPs and extracted effect estimates for diabetes (odds ratios) and for glycaemic traits (beta estimates) together with accompanying standard\nerrors from the published large GWAS data.3 We applied inverse-variance weighted (IVW) regression and performed MR Egger-regression to calculate causal estimates making use of these summary data.12 IVW was applied by carrying out a meta-analysis of estimates using both fixed-effects (reported in Supplementary Table 5, available as Supplementary Data at IJE online) and random-effects models (reported in the main text and in Table 1) to obtain pooled estimates of the effect of GGT on diabetes or glycaemic traits, as previously described.13 Heterogeneity is quantified in the random-effects model with the parameter I2, which indicates the percentage of variance in the estimate that is attributable to the variability in the effect size between instruments, as opposed to the variability that is due to measurement error. We also calculated MR-Egger estimates—a recently proposed method for MR analysis, which is robust to invalid instruments. It is used to test for directional pleiotropy and provides an estimate of the causal effect adjusted for its presence.\nFor MR analyses of diabetes, we estimated power using the online tool mRnd (http://cnsgenomics.com/shiny/ mRnd/). We used the genetic sample size and case/control ratios together with the proportion of variance of GGT explained by the GRS. We calculated power to detect an effect using type 1 error (a) of 0.05.\nProportional hazard assumptions were inspected visually using log-minus-log plots, with no deviations detected for both the observational and genetic analysis. Statistical analyses were done using SPSS version 20 (IBM, Armonk, NY, USA), Stata release 13 software (StataCorp LP, College Station, TX, USA) and R version 2.15.1 (R Foundation\nfor Statistical Computing, Vienna, Austria). Missing values for all covariates were imputed using expectation maximization in SPSS."
    }, {
      "heading" : "Results",
      "text" : "Baseline characteristics of the population used for analysis from the Rotterdam Study are shown in Table 2. Mean age (SD) of participants was 65.6 (9.8), 58% of the population were women and mean serum GGT level was 24 U/L. During a mean follow-up time of 5.7 years, 1125 individuals progressed to prediabetes {incidence rate: 27.1 [95% confidence interval (CI)] per 1000 person-years}. For type 2 diabetes, the mean follow-up was 6.9 years and 811 individuals developed diabetes [incidence rate: 13.6 (95% CI) per 1000 person-years].\nThe age- and sex-adjusted HRs for prediabetes per 1-SD change in natural logarithm of GGT was 1.26 (95% CI: 1.19–1.34), as shown in Table 3. Further adjustments for BMI and ALT yielded a HR of 1.16 (95% CI: 1.09–1.25). Controlling for conventional risk factors in model 3 diminished the magnitude of the association (HR¼ 1.10; 95% CI: 1.02–1.19), and adjustment for fasting glucose and fasting insulin did not materially change the estimate. For type 2 diabetes, the age- and sex-adjusted HR was 1.39 (95% CI: 1.30–1.49).\nThe estimate was attenuated after adjustment for BMI and ALT (HR¼ 1.27; 95% CI: 1.07–1.2). The association further attenuated after adjustment for confounders and for fasting glucose and fasting insulin (HR¼1.19; 95% CI: 1.1–1.3). Figure 2 depicts a graphical representation of\nthe distribution of GGT levels with incremental increase in HRs for prediabetes and diabetes over the range of GGT in the Rotterdam Study.\nGGT-related genetic variants and risk of prediabetes and type 2 diabetes\nNearly all GGT SNPs were associated with GGT levels in the Rotterdam Study (Supplementary Table 2, available as Supplementary Data at IJE online). However, none of them was associated with prediabetes and type 2 diabetes (Supplementary Figure 1a and b, available as Supplementary Data at IJE online). The GRS composed of\n26 SNPs was normally distributed among the study participants and associated with log-transformed GGT levels (beta per SD log GGT¼0.41, 95% CI: 0.35–0.47, P-value¼ 2 10–16), explaining 3.5% of the variation in serum GGT (F-statistic¼ 91.9). Supplementary Figure 2 (available as Supplementary Data at IJE online) shows increasing mean levels of GGT in quartiles of the GRS. The GRS did not associate with the risk of prediabetes (HR per SD in log GGT¼ 0.90; 95% CI: 0.67–1.22) and type 2 diabetes (HR per SD in log GGT¼ 0.86; 95% CI: 0.60–1.23) (Table 4). Furthermore, there was no evidence for an effect of GGT genetic score on glycaemic traits in the Rotterdam Study (Table 4). Stratification by drinking status did not affect the genetic association of GGT with the risk of diabetes. Excluding prevalent CVD cases did not affect the estimates (Supplementary Table 3, available as Supplementary Data at IJE online). Combining prevalent and incident cases of type 2 diabetes did not change the results (Supplemental Table 3, available as Supplementary Data at IJE online). Excluding SNPs that had a pleiotropic effect did not affect the association between GGT GRS, prediabetes and type 2 diabetes (Supplementary Table 4, available as Supplementary Data at IJE online). Previously reported genetic variant (rs2017869) in the GGT1 gene was negatively associated with GGT levels (beta per SD in log GGT¼ –0.06; 95% CI: –0.07 to –0.05; P-value< 2 10–16) and it explained 2.6% of the variance in the GGT levels (F-statistic: 68.82). In a separate genetic analysis of rs2017869, we found no effect of the genetic variant neither with prediabetes nor with diabetes risk in the Rotterdam Study (Table 4).\nTaking advantage of the large sample size, we then evaluated causal estimates in publically available GWAS. With the IVW, we detected no evidence for a causal relation between GGT and diabetes (log OR per SD of log GGT¼ 0.107, 95% CI: 0.275 to 0.086, P-value¼0.10) and the same null result was observed with MR-Egger\nestimate (log OR per SD of log GGT¼ 0.149, 95% CI: ( 0.187 to 0.484, P-value¼ 0.36) (Table 1). Scatter plot for the genetic associations of SNPs and type 2 diabetes is depicted in Figure 3. Likewise, no causal association of GGT was detected for any other of glycaemic traits employing IVW or MR-Egger estimates. Visual plots of the genetic association of GGT with glycaemic traits are shown in Supplementary Figure 3a–c (available as Supplementary Data at IJE online).\nMaking use of the online power calculator, we estimated to have >80% power to detect an HR> 1.11 per SD of log GGT for diabetes."
    }, {
      "heading" : "Discussion",
      "text" : "In this population-based cohort study, we found a 10% higher risk of prediabetes and a 19% higher risk of diabetes per SD increase in serum GGT levels. The MR analysis using GGT-related genetic variant as instrumental variables did not support this association to be causal. Altogether, our results suggest that the association could be mainly due to reverse causation or possible confounding.\nAlthough a large and broadly consistent body of evidence has established serum GGT levels as strongly linked to the development of type 2 diabetes, its causal role is\nuncertain. It is suggested that GGT links to type 2 diabetes through hepatic lipid accumulation and non-alcoholic fatty liver disease (NAFLD), both implicated in impaired hepatic insulin resistance, major features of pathophysiology of type 2 diabetes.14 In addition, GGT is involved in the catabolism of glutathione and is associated with increased oxidative stress, which is involved in the development of insulin resistance and diabetes.15,16 This evidence is confirmed from animal models that relate dysregulated glutathione metabolism with impaired insulin action in adipocytes.17 However, GGT could also be associated with type 2 diabetes and glycaemic traits based on reverse causality. We observed in our study that further adjustment for potential confounders or mediators, including fasting glucose and insulin as well, considerably diluted the association. In agreement with this observation, a recent study from Scott et al. found that a genetically determined insulin resistance was associated with increasing GGT levels,18 suggesting a causal role of insulin resistance in GGT. We were able to replicate these findings in the Rotterdam Study employing a reverse MR study for GGT. Insulinrelated GRS utilizing nine genetic variants11 was associated with higher GGT levels (effect estimate: 0.001; 95% CI: 0.0001–0.002). Taken altogether, our findings may therefore more favourably indicate reverse causality.\nThe direction of estimates in the observational analysis is in line with a previous meta-analysis of 24 cohort studies1 that reported a pooled relative risk of top vs bottom tertiles of GGT levels with type 2 diabetes incidence of 1.34 (1.27–1.42). However, the substantial heterogeneity (I2> 70%) observed between studies, together with the younger mean age of participants (50 years old vs 65.6 years old in our study) might explain the difference in magnitude with our study. The effect estimates in our analysis were substantially and steeply attenuated by adjustment for conventional risk factors and confounders across models. This suggests that potential residual and unmeasured confounders remain a concern and might explain the association.\nOur genetic analysis suggests that GGT is not causally affecting glycaemic traits, prediabetes or risk of type 2 diabetes. Nevertheless, there is evidence to suggest that the GGT1 locus, which is the main protein-coding gene for GGT, may account for serum GGT levels variation18,19 and therefore variants within this locus have been used as instrumental variables for MR studies. Conen and colleagues2 used an MR approach and found evidence for a causal effect of a GGT1 variant on fasting insulin levels in a sample size of 4000 participants. The instrumental variable (rs2017869) was explaining only 1.6% of the variance of GGT levels. These results were not replicated in the Rotterdam Study. Similarly, we could not replicate the causal analysis when using the multi-locus genetic instrument (explaining 3.5% of the variance in GGT levels). Although the\nRotterdam Study sample size could not help to yield highprecision estimates from the genetic analysis, we were unable to confirm an association in the GWAS data where we had >80% power to detect an HR of 1.11 of GGT levels on type 2 diabetes risk.20 MR is a suitable alternative to explore evidence for causality when certain assumptions are met. First, there should be a strong association between the GRS and the risk factor of interest. All SNPs used in our study were associated with GGT levels in a large meta-analyses of GWAS.4 Second, the effect of genetic instrument on the outcome must be mediated exclusively by the exposure and there should be no direct effects (e.g. a causal pathway between the genetic variants and outcome that does not involve the exposure and that can be introduced by horizontal pleiotropy or population stratification). Third, GRS affects the outcome only through the risk factor of interest. This assumption should be considered using information on the underlying biology, as it is difficult to validate whether the instrument satisfies the no-pleiotropy assumption. In our analysis, GCKR, SLC2A2 and HNF1A have been reported to be associated with glucose21 and type 2 diabetes.22 Other genetic variants have been reported to be associated with serum CRP,23 low-density lipoprotein cholesterol and coronary artery disease.24 When we excluded the pleiotropic variants from the GRS in a sensitivity analysis, the causal estimates did not change. Thus, it is unlikely that our results are affected by potential pleiotropy. This is in line with our results from MR-Egger-regression estimates utilizing GWAS summary-level data.\nThe major strength of this study is the large sample size for measurements of both GGT and glycaemic indices, prediabetes and diabetes in the Rotterdam Study, and the additional sample size secured through utilization of the GWAS data. By also examining associations with incident prediabetes, we provided insight into the early development of metabolic dysregulations that could lead to diabetes. Additionally, we used data from a wellcharacterized prospective population-based cohort study, which allowed us to have a comprehensive assessment of this association using both observational and genetic data. Nevertheless, several issues may compromise our approach in assessing causality. First, it could be argued that, as the biological function for some of the GGT SNPs is yet to be established, there could be alternative biological pathways explaining their association with GGT. Using multiple SNPs to index GGT, we were able to minimize the risk of pleiotropic effects, as the effects of alternative pathways reflected by individual SNPs would be expected to be strongly diluted when combined in a multi-marker score. Second, using SNPs from GWAS, where the lead SNPs with the smallest P-values are typically selected and other significant SNPs are not reported, could lead to"
    }, {
      "heading" : "GRS",
      "text" : "CI, confidence interval; GGT, gamma-glutamyltransferase; HOMA-IR, homeostatic model assessment-insulin resistance; model adjusted only for study cohort effect aEffect estimates represent betas for continuous traits and HRs for binary outcomes. Results are reported per SD change in GGT GRS in the Rotterdam Study.\noverestimation of the SNP-trait effect reflected in the MR analysis. This might be due to chance correlation between these SNPs and potential confounders. However, the genetic variants selected as instruments were strongly associated with GGT levels in both the GWA study and in the current study.\nAdditionally, we only used GGT measured in serum, but there have been reported differences in plasma levels and different types of GGT fractions.25,26 Furthermore, the\nresults may not be valid for all ethnic groups, since our population consisted of Caucasian individuals.\nIn conclusion, we cannot verify any causal effect of GGT on prediabetes and diabetes risk. The observed association between GGT levels and the risk of prediabetes and type 2 diabetes is probably due to reverse causation or residual confounding. This implies that interventions to lower GGT levels are unlikely to result in decreased risk of diabetes."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission; and the Municipality of Rotterdam. J.N. has been financially supported by Erasmus Mundus Western Balkans (ERAWEB), a project funded by the European Commission. A.D. is supported by a NWO grant (veni, 916.12.154) and the EUR Fellowship. O.H.F. works in Erasmus AGE, a centre for ageing research across the life course funded by Nestlé Nutrition (Nestec Ltd), Metagenics Inc. and AXA. Nestlé Nutrition (Nestec Ltd), Metagenics Inc. and AXA had no role in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. J.N. researched, analysed the data and wrote the manuscript. T.M., S.L., A.H., S.M., H.J., O.F. and A.D. reviewed/ edited the manuscript. All authors approved the final version.\nConflicts of interests: None declared."
    } ],
    "references" : [ {
      "title" : "Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis",
      "author" : [ "SK Kunutsor", "A Abbasi", "AI. Adler" ],
      "venue" : "Ann Epidemiol",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2014
    }, {
      "title" : "Use of a Mendelian Randomization approach to assess the causal relation of gammaglutamyltransferase with blood pressure and serum insulin levels",
      "author" : [ "D Conen", "P Vollenweider", "V Rousson" ],
      "venue" : "Am J Epidemiol",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2010
    }, {
      "title" : "Mendelian Randomization analysis with multiple genetic variants using summarized data",
      "author" : [ "Burgess SBA", "Thompson SG" ],
      "venue" : "Genet Epidemiol",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2013
    }, {
      "title" : "Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma",
      "author" : [ "JC Chambers", "WH Zhang", "J Sehmi" ],
      "venue" : "Nat Genet 2011;43:1131–U129",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2011
    }, {
      "title" : "Current applications of genetic risk scores to cardiovascular outcomes and subclinical phenotypes",
      "author" : [ "JA Smith", "EB Ware", "P Middha" ],
      "venue" : null,
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2015
    }, {
      "title" : "Mendelian Randomization studies of biomarkers and type 2 diabetes",
      "author" : [ "A. Abbasi" ],
      "venue" : "Endocr Connect 2015;4:249–60",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2015
    }, {
      "title" : "The Rotterdam Study: 2016 objectives and design update",
      "author" : [ "A Hofman", "GG Brusselle", "S Darwish Murad" ],
      "venue" : "Eur J Epidemiol",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2015
    }, {
      "title" : "Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study",
      "author" : [ "MJG Leening", "M Kavousi", "J Heeringa" ],
      "venue" : "Eur J Epidemiol",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2012
    }, {
      "title" : "Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes",
      "author" : [ "AP Morris", "BF Voight", "TM Teslovich" ],
      "venue" : null,
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2012
    }, {
      "title" : "Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways",
      "author" : [ "RA Scott", "V Lagou", "RP Welch" ],
      "venue" : null,
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2012
    }, {
      "title" : "Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression",
      "author" : [ "J Bowden", "G Davey Smith" ],
      "venue" : "Int J Epidemiol",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2015
    }, {
      "title" : "A Mendelian Randomization study of the effect of type-2 diabetes on coronary heart disease",
      "author" : [ "OS Ahmad", "JA Morris", "M Mujammami" ],
      "venue" : null,
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2015
    }, {
      "title" : "Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes",
      "author" : [ "TK Grønbaek H", "J Rungby", "O Schmitz" ],
      "venue" : "Expert Rev Gastroenterol Hepatol",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2008
    }, {
      "title" : "Is serum gamma glutamyltransferase a marker of oxidative stress",
      "author" : [ "Lee DH BR", "Jacobs DR Jr." ],
      "venue" : "Free Radic Res",
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2004
    }, {
      "title" : "Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited",
      "author" : [ "A Ceriello", "E. Motz" ],
      "venue" : "Arterioscl Throm Vas 2004;24:816–23",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2004
    }, {
      "title" : "Dysregulated glutathione metabolism links to impaired insulin action in adipocytes",
      "author" : [ "H Kobayashi", "M Matsuda", "A Fukuhara" ],
      "venue" : "Am J Physiol-Endoc M 2009;296:E1326–34",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2009
    }, {
      "title" : "Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity",
      "author" : [ "RA Scott", "T Fall", "D Pasko" ],
      "venue" : "Diabetes",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2014
    }, {
      "title" : "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes",
      "author" : [ "X Yuan", "D Waterworth", "JRB Perry" ],
      "venue" : "Am J Hum Genet",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2008
    }, {
      "title" : "Calculating statistical power in Mendelian Randomization studies",
      "author" : [ "MJA Brion", "K Shakhbazov", "PM. Visscher" ],
      "venue" : "Int J Epidemiol",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2013
    }, {
      "title" : "New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk",
      "author" : [ "J Dupuis", "C Langenberg", "I Prokopenko" ],
      "venue" : "Nat Genet 2010;42:105–U32",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2010
    }, {
      "title" : "Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis",
      "author" : [ "BF Voight", "LJ Scott", "V Steinthorsdottir" ],
      "venue" : "(vol 42,",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2010
    }, {
      "title" : "Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein",
      "author" : [ "AP Reiner", "MJ Barber", "Y Guan" ],
      "venue" : "Am J Hum Genet",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2008
    }, {
      "title" : "Biological, clinical and population relevance of 95 loci for blood lipids",
      "author" : [ "TM Teslovich", "K Musunuru", "AV Smith" ],
      "venue" : "Nature",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2010
    }, {
      "title" : "Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study",
      "author" : [ "M Franzini", "I Fornaciari", "J Rong" ],
      "venue" : "Clin Chim Acta 2013;417:19–25",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2013
    }, {
      "title" : "Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals",
      "author" : [ "M Franzini", "A Paolicchi", "I Fornaciari" ],
      "venue" : "Clin Chem Lab Med 2010;48:713–17",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Circulating serum levels of gamma-glutamyltransferase (GGT) have been associated with increased risk of prediabetes and type 2 diabetes in observational studies.(1) A meta-analysis of 24 cohorts reported 34% higher diabetes risk in a comparison of extreme thirds of baseline levels of GGT.",
      "startOffset" : 161,
      "endOffset" : 164
    }, {
      "referenceID" : 0,
      "context" : "A meta-analysis of 24 cohorts reported 34% higher diabetes risk in a comparison of extreme thirds of baseline levels of GGT.(1) It is, however, unclear whether the association between GGT and diabetes is free of unobserved confounding.",
      "startOffset" : 124,
      "endOffset" : 127
    }, {
      "referenceID" : 1,
      "context" : "A previous study from Switzerland (4360 individuals) used a single-nucleotide polymorphism (SNP) in the GGT1 gene to study the causal relation between GGT and fasting insulin levels employing a Mendelian Randomization (MR) approach.(2) This SNP explains merely 1.",
      "startOffset" : 232,
      "endOffset" : 235
    }, {
      "referenceID" : 2,
      "context" : "It is known that a weak instrumental variable makes the association susceptible to false positive findings.(3) So far, 26 loci have been identified for serum GGT levels.",
      "startOffset" : 107,
      "endOffset" : 110
    }, {
      "referenceID" : 3,
      "context" : "So far, 26 loci have been identified for serum GGT levels.(4) Thus, a genetic risk score (GRS) combining the effect of all these loci could provide a stronger instrument for the MR analysis to infer causality.",
      "startOffset" : 58,
      "endOffset" : 61
    }, {
      "referenceID" : 4,
      "context" : "Thus, a genetic risk score (GRS) combining the effect of all these loci could provide a stronger instrument for the MR analysis to infer causality.(5) Additionally, GGT has not been previously investigated as a causal biomarker for diabetes, as reported from a recent systematic review from Abbasi.",
      "startOffset" : 147,
      "endOffset" : 150
    }, {
      "referenceID" : 5,
      "context" : "Additionally, GGT has not been previously investigated as a causal biomarker for diabetes, as reported from a recent systematic review from Abbasi.(6) In this study, we investigated the association between serum GGT levels and risk of incidence prediabetes and type 2 diabetes in a large prospective population-based cohort study of participants aged 45 years.",
      "startOffset" : 147,
      "endOffset" : 150
    }, {
      "referenceID" : 6,
      "context" : "A more detailed description of the Rotterdam Study can be found elsewhere.(7) The Rotterdam Study has been approved by the medical ethics committee according to the Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands.",
      "startOffset" : 74,
      "endOffset" : 77
    }, {
      "referenceID" : 7,
      "context" : "Follow-up data were complete until 1 January 2012.(9) Information on study model covariates can be found in Supplementary Table 1 (available as Supplementary Data at IJE online).",
      "startOffset" : 50,
      "endOffset" : 53
    }, {
      "referenceID" : 3,
      "context" : "In this study, we selected 26 SNPs that passed the genome-wide significance threshold (P-value< 5 10) for serum GGT levels.(4) Supplementary Table 2 (available as Supplementary Data at IJE online) provides an overview of the SNPs included in the genetic score for GGT and weights assigned to each SNP.",
      "startOffset" : 123,
      "endOffset" : 126
    }, {
      "referenceID" : 3,
      "context" : "Taking into consideration any pleiotropic effect of the SNPs included in the genetic score, we reanalysed the genetic estimates excluding SNPs that have previously been reported to be associated with cardiometabolic traits (rs1260326, rs10513686, rs4074793, rs17145750, rs7310409, rs516246).(4)",
      "startOffset" : 291,
      "endOffset" : 294
    }, {
      "referenceID" : 8,
      "context" : "For diabetes, we used data from the DIAGRAM consortium, which meta-analysed genetic variants in 34 840 case subjects with diabetes and 114 981 control subjects from 37 studies.(10) For fasting glucose (n1⁄4 58 074), fasting insulin (n1⁄4133 000) and HOMAinsulin resistance (n1⁄437 073), we used data from the Meta-Analyses of Glucose and Insulin-related Traits Consortium (MAGIC), which is a collaborative effort that combined data from 55 studies to identify genetic determinants that affect glycaemic traits.",
      "startOffset" : 176,
      "endOffset" : 180
    }, {
      "referenceID" : 9,
      "context" : "Participants were of European ancestry and genotyped with the Metabochip.(11) We selected 26 GGT-related SNPs and extracted effect estimates for diabetes (odds ratios) and for glycaemic traits (beta estimates) together with accompanying standard 4 International Journal of Epidemiology, 2017, Vol.",
      "startOffset" : 73,
      "endOffset" : 77
    }, {
      "referenceID" : 2,
      "context" : "errors from the published large GWAS data.(3) We applied inverse-variance weighted (IVW) regression and performed MR Egger-regression to calculate causal estimates making use of these summary data.",
      "startOffset" : 42,
      "endOffset" : 45
    }, {
      "referenceID" : 10,
      "context" : "We applied inverse-variance weighted (IVW) regression and performed MR Egger-regression to calculate causal estimates making use of these summary data.(12) IVW was applied by carrying out a meta-analysis of estimates using both fixed-effects (reported in Supplementary Table 5, available as Supplementary Data at IJE online) and random-effects models (reported in the main text and in Table 1) to obtain pooled estimates of the effect of GGT on diabetes or glycaemic traits, as previously described.",
      "startOffset" : 151,
      "endOffset" : 155
    }, {
      "referenceID" : 11,
      "context" : "IVW was applied by carrying out a meta-analysis of estimates using both fixed-effects (reported in Supplementary Table 5, available as Supplementary Data at IJE online) and random-effects models (reported in the main text and in Table 1) to obtain pooled estimates of the effect of GGT on diabetes or glycaemic traits, as previously described.(13) Heterogeneity is quantified in the random-effects model with the parameter I(2), which indicates the percentage of variance in the estimate that is attributable to the variability in the effect size between instruments, as opposed to the variability that is due to measurement error.",
      "startOffset" : 343,
      "endOffset" : 347
    }, {
      "referenceID" : 12,
      "context" : "It is suggested that GGT links to type 2 diabetes through hepatic lipid accumulation and non-alcoholic fatty liver disease (NAFLD), both implicated in impaired hepatic insulin resistance, major features of pathophysiology of type 2 diabetes.(14) In addition, GGT is involved in the catabolism of glutathione and is associated with increased oxidative stress, which is involved in the development of insulin resistance and diabetes.",
      "startOffset" : 241,
      "endOffset" : 245
    }, {
      "referenceID" : 13,
      "context" : "In addition, GGT is involved in the catabolism of glutathione and is associated with increased oxidative stress, which is involved in the development of insulin resistance and diabetes.(15,16) This evidence is confirmed from animal models that relate dysregulated glutathione metabolism with impaired insulin action in adipocytes.",
      "startOffset" : 185,
      "endOffset" : 192
    }, {
      "referenceID" : 14,
      "context" : "In addition, GGT is involved in the catabolism of glutathione and is associated with increased oxidative stress, which is involved in the development of insulin resistance and diabetes.(15,16) This evidence is confirmed from animal models that relate dysregulated glutathione metabolism with impaired insulin action in adipocytes.",
      "startOffset" : 185,
      "endOffset" : 192
    }, {
      "referenceID" : 15,
      "context" : "This evidence is confirmed from animal models that relate dysregulated glutathione metabolism with impaired insulin action in adipocytes.(17) However, GGT could also be associated with type 2 diabetes and glycaemic traits based on reverse causality.",
      "startOffset" : 137,
      "endOffset" : 141
    }, {
      "referenceID" : 18,
      "context" : "11 of GGT levels on type 2 diabetes risk.(20) MR is a suitable alternative to explore evidence for causality when certain assumptions are met.",
      "startOffset" : 41,
      "endOffset" : 45
    }, {
      "referenceID" : 3,
      "context" : "All SNPs used in our study were associated with GGT levels in a large meta-analyses of GWAS.(4) Second, the effect of genetic instrument on the outcome must be mediated exclusively by the exposure and there should be no direct effects (e.",
      "startOffset" : 92,
      "endOffset" : 95
    }, {
      "referenceID" : 20,
      "context" : "In our analysis, GCKR, SLC2A2 and HNF1A have been reported to be associated with glucose(21) and type 2 diabetes.(22) Other genetic variants have been reported to be associated with serum CRP,(23) low-density lipoprotein cholesterol and coronary artery disease.",
      "startOffset" : 113,
      "endOffset" : 117
    }, {
      "referenceID" : 22,
      "context" : "Other genetic variants have been reported to be associated with serum CRP,(23) low-density lipoprotein cholesterol and coronary artery disease.(24) When we excluded the pleiotropic variants from the GRS in a sensitivity analysis, the causal estimates did not change.",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 23,
      "context" : "Additionally, we only used GGT measured in serum, but there have been reported differences in plasma levels and different types of GGT fractions.(25,26) Furthermore, the results may not be valid for all ethnic groups, since our population consisted of Caucasian individuals.",
      "startOffset" : 145,
      "endOffset" : 152
    }, {
      "referenceID" : 24,
      "context" : "Additionally, we only used GGT measured in serum, but there have been reported differences in plasma levels and different types of GGT fractions.(25,26) Furthermore, the results may not be valid for all ethnic groups, since our population consisted of Caucasian individuals.",
      "startOffset" : 145,
      "endOffset" : 152
    } ],
    "year" : 2017,
    "abstractText" : "Background: High levels of serum gamma-glutamyltransferase (GGT) are associated with increased risk of prediabetes and type 2 diabetes in observational studies. It is unclear whether this relationship is causal, arises from residual confounding or is a consequence of reverse causation. Methods: We used data from a prospective population-based cohort study, compromising 8611 individuals without diabetes at baseline. Cox proportional hazard models were used to study the association between serum GGT levels and incident prediabetes and diabetes. A Mendelian Randomization (MR) study was performed using a genetic risk score consisting of 26 GGT-related variants, based on a genome-wide association study (GWAS) on liver enzymes. Association with diabetes and glycaemic traits were investigated within the Rotterdam Study and large-scale GWAS. Results: During follow-up, 1125 cases of prediabetes (mean follow-up 5.7 years) and 811 cases of type 2 diabetes (6.9 years) were ascertained. The predicted hazard ratios per standard deviation (SD) change in GGT levels in the multivariable model were 1.10 for prediabetes [95% confidence interval (CI): 1.02–1.19] and 1.19 for type 2 diabetes (95% CI: 1.10–1.30). The genetic risk score associated with increased GGT levels (beta per SD log GGT1⁄4 0.41, 95% CI: 0.35–0.47), explaining 3.5% of the observed variation in GGT. MR analysis did not provide evidence for a causal role of GGT, with a causal relative risk for prediabetes and type 2 diabetes per SD of log GGT of 0.97 (95% CI: 0.91–1.04) and 0.96 (95% CI: 0.89–1.04), respectively. Multiple instrumental analysis using genetic associations with type 2 diabetes and glycaemic traits from previous GWA studies detected no causal effect of GGT. VC The Author 2017; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 1 International Journal of Epidemiology, 2017, 1–10 doi: 10.1093/ije/dyx006",
    "creator" : "Arbortext Advanced Print Publisher 9.0.114/W"
  }
}